Immune-Modified Response Criteria in Solid Tumours
Analyzis of atezolizumab data in clinical trials including NSCLC, mUC, RCC and melanoma patients may inform additional modifications to response evaluation criteria
Read full article (External website)
Leave a Reply
Want to join the discussion?Feel free to contribute!